Attached files
| file | filename |
|---|---|
| 10-Q - ONCOVISTA INNOVATIVE THERAPIES, INC | v193872_10-q.htm |
| EX-32 - ONCOVISTA INNOVATIVE THERAPIES, INC | v193872_ex32.htm |
| EX-31.1 - ONCOVISTA INNOVATIVE THERAPIES, INC | v193872_ex31-1.htm |
EX-31.2
CERTIFICATION
OF CHIEF FINANCIAL OFFICER
PURSUANT
TO THE SECURITIES EXCHANGE ACT OF 1934,
RULES
13a-14(a) AND 15d-14(a)
AS
ADOPTED PURSUANT TO
SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002
I,
Alexander L. Weis, certify that:
1. I have
reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2010
of OncoVista Innovative Therapies, Inc. (the "registrant");
2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by
this report;
3. Based
on
my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this
report;
4.
The registrant's other certifying officer(s) and
I are responsible for establishing and
maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such
disclosure controls
and procedures to be designed under our
supervision, to ensure that material information relating to
the registrant, including its consolidated
subsidiaries, is made known to us by others within those
entities, particularly during the period in which this
report is being prepared;
(b)
Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in
accordance with generally accepted accounting
principles;
(c)
Evaluated the effectiveness of the registrant's disclosure control and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and
(d)
Disclosed in this report any change in
the registrant's internal control over
financial reporting that occurred during the registrant's
most recent fiscal quarter that has materially affected, or is
reasonably likely
to materially affect, the registrant's internal
control over financial reporting; and
5. The
registrant's other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control
over financial reporting, to the
registrant's auditors and the
audit committee of
the registrant's board of directors (or persons performing
the equivalent functions):
(a) All
significant deficiencies and material weaknesses in the design or
operation of internal control
over financial reporting which are
reasonably likely
to adversely affect the registrant's ability
to record, process, summarize and report financial information; and
(b) Any
fraud, whether or not
material, that involves management or
other employees who have
a significant role in the registrant's
internal control over financial reporting.
Date:
August 16, 2010
/s/ Alexander L. Weis, Ph.D.
Alexander
L. Weis, Ph.D.
Chief
Financial Officer